Is Coenzyme Q10 Statin Myalgia Meta-Analysis safe?

Updated May 2026

Quick Answer

Coenzyme Q10 Statin Myalgia Meta-Analysis has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: They can cause various side effects, in particular statin-associated muscle symptoms (SAMS) associated with mitochondrial dysfunction and micronutrient depletion.

Key Takeaways

  • 01They can cause various side effects, in particular statin-associated muscle symptoms (SAMS) associated with mitochondrial dysfunction and micronutrient depletion. [Kovacic S (2025)]
  • 02Overall, a significant reduction in SAMS, measured as pain intensity, after CoQ10 supplementation was found: weighted mean difference (WMD) -0.96 (95% Confidence Interval -1.88; -0.03), p < 0.05. [Kovacic S (2025)]
  • 03Statins are effective drugs for lowering hypercholesterolemia and preventing cardiovascular diseases. [Kovacic S (2025)]
  • 04Despite major advancements in pharmacotherapies and interventional cardiology, substantial residual risk persists among patients with established disease (). [Wu Xun (2026)]
The current Migaku evidence database contains 2 reusable source documents for Coenzyme Q10 Statin Myalgia Meta-Analysis. This answer focuses on safety, limits, and clinician-discussion contexts. - They can cause various side effects, in particular statin-associated muscle symptoms (SAMS) associated with mitochondrial dysfunction and micronutrient depletion. [Kovacic S (2025); evidence level 1] - Overall, a significant reduction in SAMS, measured as pain intensity, after CoQ10 supplementation was found: weighted mean difference (WMD) -0.96 (95% Confidence Interval -1.88; -0.03), p < 0.05. [Kovacic S (2025); evidence level 1] - Statins are effective drugs for lowering hypercholesterolemia and preventing cardiovascular diseases. [Kovacic S (2025); evidence level 1] - Despite major advancements in pharmacotherapies and interventional cardiology, substantial residual risk persists among patients with established disease (). [Wu Xun (2026); evidence level 3] - Additionally, many nutraceuticals are perceived to possess favorable safety and tolerability profiles compared to conventional medications, making them attractive for long-term risk reduction (). [Wu Xun (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Effects of coenzyme Q10 supplementation on myopathy in statin-treated patients: a systematic review and meta-analysis.
  2. Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives